Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Learning disability" patented technology

Learning disability, learning disorder or learning difficulty (British English) is a condition in the brain that causes difficulties comprehending or processing information and can be caused by several different factors. Given the "difficulty learning in a typical manner", this does not exclude the ability to learn in a different manner. Therefore, some people can be more accurately described as having a "learning difference", thus avoiding any misconception of being disabled with a lack of ability to learn and possible negative stereotyping. In the United Kingdom, the term "learning disability" generally refers to an intellectual disability, while difficulties such as dyslexia and dyspraxia are usually referred to as "learning difficulties".

Use of methylated peptide as therapeutic agent for degenerative brain diseases

PCT designated stageWO2026079944A1Nervous disorderPeptide/protein ingredientsAmyloid betaEfficacy
The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.
Owner:KINE SCI CO LTD

Herbal extract composition for improving cognitive and learning abilities

PCT designated stageWO2026142022A1FormularyHerb medicine
The present invention relates to a composition for improving cognitive function or learning ability and preventing or treating cognitive impairment or learning disorder. When the pharmaceutical composition or the food composition comprising a complex herbal medicine extract of the present invention is used, the cognitive function or learning ability of a subject can be effectively improved, and thus cognitive impairment or learning disorder can be treated.
Owner:BICHEDAM CO LTD

Modulators of g protein-coupled receptor 88

PCT designated stageWO2026055419A1Nervous disorderOrganic chemistryHuntingtons choreaAttention deficit hyperkinetic disorder
N-([1,1'-biaryl]-4-yl)-N-((1-hydroxycycloalkyl)methyl)-2-(aryl)cyclopropane-1-carboxamide compounds (I) and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, tardive dyskinesia, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease, basal ganglia disorders, and tardive dyskinesia.
Owner:ACADIA PHARMACEUTICALS INC

Iron supplementation in neurodevelopmental or psychiatric disorder

PCT designated stageWO2026017901A1Heavy metal active ingredientsNervous disorderNeuro developmentLearning disability
Subject matter of the present invention is supplementation for treatment and / or prophylaxis of a neurodevelopmental or psychiatric disorder in a human patient in need thereof, wherein said patient suffers from a neurodevelopmental or psychiatric disorder selected from the group comprising attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), impulse control disorder and learning disorder and wherein said iron supplementation is selected from the group comprising an intravenous iron supplementation, parenteral iron supplementation, oral iron supplementation, intraaerterial iron supplementation or intramuscular iron supplementation, preferably an intravenous iron supplementation.
Owner:MALIAN BIOLOGICALS GMBH